secondary progressive MS Archive

Teaserbild für ein Video über eine Neuzulassung eines Medikamentes gegen Multiple Sklerose. EMA lässt Tolebrutinib zu: Videotitel, weiße Tabletten, Videopfeil für Play

EMA approves Tolebrutinib

10. July 2026 Prof. Dr. med. Mathias Mäurer General

At the end of June, the European Medicines Agency (short: EMA) approved the Bruton’s tyrosine kinase inhibitor Tolebrutinib (amsel.de reported immediately). The BTKi is approved for the indication of secondary progressive multiple sclerosis without relapses

zwei runde, weiße Tabletten vor weißem Hintergrund

New Year, new on BTKi: PERSEUS Study misses the primary endpoint

14. January 2026 Prof. Dr. med. Mathias Mäurer General

First of all, I would like to wish all readers of MS-DocBlog a happy and successful new year. – Stay healthy and hopeful, despite all adversities. Speaking of adversities – this brings us right back

Approval of Siponimod in the USA and Europe – the vote of the regulatory authorities

18. November 2019 Prof. Dr. med. Mathias Mäurer MS Therapy

The new MS drug Siponimod, the further development of Fingolimod (Gilenya®), was recently approved by the Food and Drug Administration (FDA) in the USA and has been available there for some time for MS patients

Tag: secondary progressive MS

EMA approves Tolebrutinib

New Year, new on BTKi: PERSEUS Study misses the primary endpoint

Approval of Siponimod in the USA and Europe – the vote of the regulatory authorities

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community